Oral erythromycin and the risk of sudden death.
Kaplan
Edward L
EL
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors*; D051544:Cytochrome P-450 CYP3A; D016757:Death, Sudden, Cardiac / Q000209:etiology*; D004347:Drug Interactions; D004917:Erythromycin / Q000009:adverse effects*; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D018942:Macrolides / Q000627:therapeutic use; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors*
D000900:Anti-Bacterial Agents; D018942:Macrolides; D004917:Erythromycin; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating